Reducing the risk of contamination of sterile parenteral products via ready-to-use closure components.
The preparation of sterile parenteral products requires careful control of all ingredients, materials, and processes to ensure the final product has the identity and strength, and meets the quality and purity characteristics that it purports to possess. Contamination affecting these critical properties of parenteral products can occur in many ways and from many sources. The use of closures supplied by manufacturers in a ready-to-use state can be an effective method for reducing the risk of contamination and improving the quality of the drug product. This article will address contamination attributable to elastomeric container closure components and the regulatory requirements associated with container closure systems. Possible contaminants, including microorganisms, endotoxins, and chemicals, along with the methods by which these contaminants can enter the product will be reviewed. Such methods include inappropriate material selection, improper closure preparation processes, compromised container closure integrity, degradation of closures, and leaching of compounds from the closures.
West Pharmaceutical Services, Inc., Lionville, PA, USA. Wayne_Curry@westpharma.com
Wayne
W
Curry
Samuel
S
Conway
Clara
C
Goodfield
Kimberly
K
Miller
Ronald L
RL
Mueller
Eugene
E
Polini
D004340:Drug Contamination / Q000517:prevention & control*; D004345:Drug Industry; D004349:Drug Packaging / Q000331:legislation & jurisprudence; D020724:Elastomers; D007263:Infusions, Parenteral; D012306:Risk; D013242:Sterilization
D020724:Elastomers